Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/533,798
INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*		APPLICANT Miles William CARROLL et al.	
		FILING DATE 3/24/2000	GROUP ART UNIT 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	5,118,672	06/92	Schinazi et al.	514	47	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
	A2	99/15684	04/99	WIPO				
	A3	99/15683	04/99	WIPO				
	A4	89/07947	09/89	WIPO				
	A5	92/03568	03/92	WIPO				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A6	**Guschlbauer et al.**, "Poly-2'-deoxy-2'-fluoro-cytidylic acid: enzymatic synthesis, spectroscopic Characterization and interaction with poly-inosinic acid" 1977 Nucleic Acids Res. 4:1933
	A7	**Schibahara et al.**, "Site-directed cleavage of RNA" 1987 Nucleic Acids Res. 15:4403
	A8	**Gershon et al**, "The nucleotide sequence around the capripoxvirus thymidine kinase gene reveals a gene Shared specifically with leporipoxvirus" J. Gen. Virol. 70:525, 1989
	A9	**Weir et al.**, "Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous Frameshift mutations" J. Virol. 46:530 ,1983
	A10	**Esposito et al.**, "Nucleotide sequence of the thymidine kinase gene region of monkeypox and variola viruses" Virology 135:561, 1984
	A11	**Kilpatrick et al.**, "Cloning and physical mapping of yada monkey tumor virus DNA" Virology 143:399, 1985
	A12	**Binns et al.**, "Comparison of a conserved region in fowlpox virus and vaccinia virus gnomes and the translocation of the fowlpox virus thymidine kinase gene"J. Gen. Virol 69:1275, 1988
	A13	**Schnitzlein et al.**, "A rapid method for identifying the thymidine kinase genes of avipoxviruses" J. Virological Method 20:341, 1988
	A14	**Fathi et al.**, "Efficient targeted insertion of an unselected marker into the vaccinia virus genome" Virology 97-105, 1986

EXAMINER	**DATE CONSIDERED**

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/533,798
INFORMATION DISCLOSURE CITATION		APPLICANT Miles William CARROLL et al.	
(Use several sheets if necessary)		FILING DATE 3/24/2000	GROUP ART UNIT 1643

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A15	**Graham et al.**, "A new technique for the assay of infectivity of human adenovirus 5 DNA" Virol. 52, 456-467, 1973
	A16	**Straibinger et al.**, "Liposomes as carriers for intracellular delivery of nucleic acids" Methods in Enzymology, 101: 512-527 1983
	A17	**Studier et al.**, "Use of T7 RNA polymerase to direct expression of cloned genes" Methods in Enzymol. 185: 60-89, 1990
	A18	**Matthias et al.**, "Eukaryotic expression vectors for the analysis of mutant proteins" 1989 NAR 17, 6418
	A19	**Wootton & Federhen,** "Statistics of local complexity in amino acid sequences and sequence database" 1993, Computers and Chemistry 17:149-163
	A20	**Myers et al.**, "Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein" 1994 J. Biol. Chem 169:9319-9324
	A21	**Starzynska et al.**, "Prognostic significance of 5T4 oncofetal antigen expression in colorectal" Br. J. Cancer 1994 May; 69(5):899-902
	A22	**Starzynska et al.**, "The expression of 5T4 antigen in colorectal and gastic carcinoma" Br. J. Cancer 1992 Nov; 66(5):867-869
	A23	**Hobbs et al.**, "polynucleotides containing 2'-amino-2'-deoxyribose and 2'-azido-2'deoxyribose"1973 Biochemistry 12:5138
	A24	**Starzynska et al.**, "5T4 oncofetal antigen in gastric carcinoma and its clinical significance" Eur J. Gastroenterol Hepatol 1998 Jun;10(6)479-484
	A25	**Carsberg et al.**, "Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells" 1996, Int J Cancer Sep 27; 68(1):84-92
	A26	**Yewdell et al.**, "TAP-independent delivery of antigenic peptides to the endoplasmic reticulum: therapeutic potential and insights into TAP-dependent antigen processing" 1998 J Immunotherapy 21:127-31
	A27	**Calvert et al.**, "Fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens" J. of Virol 67:3069-3076, 1993
	A28	**Carroll et al.**, "Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen" 1998 J. Natl. Cancer Inst. 90(24):1881-1887
	A29	"Two bright new faces in gene therapy" Nature Biotechnology 1996 14; 556

EXAMINER	DATE CONSIDERED

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/533,798
INFORMATION DISCLOSURE CITATION		APPLICANT Miles William CARROLL et al.	
(Use several sheets if necessary)		FILING DATE 3/24/2000	GROUP ART UNIT 1643

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A30	**Pieken et al.**, "Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes" 1991 Science 253:314-317
	A31	**Parker et al.**, "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains" 1994 J. Immunol. 152:163-175
	A32	**Fu et al.**, "An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope" 1998 J. Virol 72:1469-81
	A33	**Schodel et al.**, "hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety" 1996 Intervirology 39:104-10
	A34	**Wolff and Trubetskoy**, "The cambrian period of nonviral gene delivery" 1998 nature Biotechnology 16:421-423
	A35	**Taylor et al.**, "Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species" 1995 Vaccine 13:539-549
	A36	**Stannard et al.**, "Evidence for incomplete replication of a penguin poxvirus in cells of mammalian origin" J. Gen. Virol. 1998 79:1637-46
	A37	**Mackett et al.**, "Vaccinia virus: a selectable eukaryotic cloning and expression vector 1982 PNAS 79: 7415-7419
	A38	**Upton et al**, "Identification and nucleotide sequence of the thymidine kinase gene of shope fibroma virus" J. Virology 60:920, 1986
	A39	**Boyle et al**, "Fowlpox virus thymidine kinase: nucleotide sequence and relationships to other thymidine kinases" Virology 156:355-365, 1987
	A40	**Lewis et al**, "Human immunodeficiency virus infection of cells arrested in the cell cycle" 1992 EMBO J 11:3053-3058
	A41	**Lewis and Emerman** "Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus" 1994 J. Virol. 68:510-516
	A42	**Mackett et al**, "General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes" 1984, J. Virol. 49:857-864

EXAMINER	DATE CONSIDERED

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/533,798
INFORMATION DISCLOSURE CITATION		APPLICANT Miles William CARROLL et al.	
(Use several sheets if necessary)		FILING DATE 3/24/2000	GROUP ART UNIT 1643

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A43	**Hruby et al**, "Fine structute analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene" PNAS 80:3411-3415, 1983
	A44	**Lytvyn et al**, "Comparison of the thymidine dinase genes from three entompoxiruses" J. Gen Virol 73:3235-3240 1992
	A45	**Smith et al.**, "Vaccinia virus immune evasion" 1997, Immunol Rev. 159:137-154
	A46	**Jenkins et al**, "Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus" AIDS Research and Human Retroviruses 7:991-998, 1991
	A47	**Taylor et al**, "Recombinant fowlpox virus inducing protective immunity in non-avian species" Vaccine 6:497-503, 1988
	A48	**Sphener et al. and Boursnell et al**, "Insertion of the fusion gene from newcastle disease virus into a non-essential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by The recombinant" 1990 J. Gen. Virol. 71:621-628
	A49	**Nakano et al**, "Molecular genetics of vaccinia virus: demonstration of marker rescue" Proc. Natl. Acad. Sci. USA 79, 1593-1596, 1982
	A50	**Chakrabarti et al.**, "Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of Recombinant virus plaques" Mol. Cell. Biol. 3403-3409, 1985
	A51	**Wigler et al**, "Transformation of mammalian cells with genes from procaryotes and eucaryotes" Cell 777-785, 1979
	A52	**Graessmann et al**,"Microinjection of tissue culture cells" Meth. Enzymology 101, 482-492, 1983
	A53	**Franke et al**, "Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants" Mol Cell biol 1918-1924, 1985
	A54	**Altenburger, W., Suter, C.P. and Altenburger J.**, "Partial deletion of the human host range gene in the attenuated vaccinia virus MVA" 1989 Arch. Virol. 105, 15-27

EXAMINER	**DATE CONSIDERED**

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/533,798
INFORMATION DISCLOSURE CITATION		APPLICANT Miles William CARROLL et al.	
(Use several sheets if necessary)		FILING DATE 3/24/2000	GROUP ART UNIT 1643

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A55	**Neumann et al.**, "Gene transfer into mouse lyoma cell by electroporation in high electric fields" EMBO J. 1, 841-845, 1982
	A56	**Schaffner**, "Direct transfer of cloned genes form bacteria to mammalian cells" Proc. Natl. Acad. Sci. USA 77,2163-2167, 1980
	A57	**Nestle FO et al**, "Vaccinatio of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells" Nat. Med. 1998 Mar;4(3):328-32
	A58	**Altschul et al**, "Issues in searching molecular sequence database" 1994 Nature Genetics 6;119-129.
	A59	**Carroll & Moss**, "Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line", 1997 Virology 238:198-211
	A60	**Kim CJ et al.**, "Dendritic cell infected with poxviruses encoding Mart-1/melan a sensitive T Lymphocytes in vitro" J. Immunother, 1997 Jul;20(4):276-86
	A61	**Schneider et al.**, "enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara" 1998 Nat Med 4:397-402
	A62	**Chakrabarti et al**, "Compact, synthetic, vaccinia virus early/late promoter for protein expression" 1997 Biotechniques 23:1094-1097
	A63	**Wyatt et al.**, "Development of replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model" 1996 Vaccine 14:1451-1458
	A64	**Sutter et al**, "A recombinant vector derived from the host range-restricted and highly attenuated MVA strain Of vaccinia virus stimulates protective immunity in mice to influenza virus", 1994 Vaccine 12:1032-1040
	A65	**Carroll and Moss** "E. *coli* β-glucuronidase (GUS) as a marker for recombinant vaccinia viruses" 1995 Biotechniques 19:352-355
	A66	**Hirsch et al.**, "Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara" 1996 J. Virol 70:3741-3752

EXAMINER	DATE CONSIDERED

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/533,798
INFORMATION DISCLOSURE CITATION		APPLICANT Miles William CARROLL et al.	
(Use several sheets if necessary)		FILING DATE 3/24/2000	GROUP ART UNIT 1643

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A67	**Sutter and Moss**, "Nonreplicating vaccinia vector efficiently expresses recombinant genes" 1992 Proc. Natl. Acad Sci USA 89:10847-10851
	A68	**Bronte et al.**, "Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine" 1997, Proc. Natl Acad Sci USA 94(7):3183-3188
	A69	**Wyatt et al.**, "Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells" 1995 Virology 210:202-205
	A70	**Carroll et al.**, "Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a Murine tumor model" 1997 Vaccine, 15:387-394
	A71	**Sutter et al**, "Non-replication vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase" 1995 FEBS lett. 371:9-12
	A72	**Overwijk et al**, "gp100/pmel 17 is a murine tumor rejectio antigen induction of "Self" - reactive, tumoricidal T cells using high-affinity, altered peptide ligand", (1998) J. Exp. Med. 188: 277-286
	A73	**Hole N, and Stern PL**, "Isolation and characterization of 5T4, a tumor-associated antigen", (1990) Int. J. Cancer 45(1): 179-184

EXAMINER	DATE CONSIDERED

- **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
		078883/0120	09/533,798

INFORMATION DISCLOSURE CITATION

APPLICANT	
Miles William CARROLL and Kevin Alan MYERS	
Date Submitted to PTO: September 6, 2000	FILING DATE: March 24, 2000 / GROUP ART UNIT: 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
	A1	EP-A-0198328	04/02/86	Europe				
	A2	EP-A-0110385	11/29/83	Europe				

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Notice of References Cited

Application No.	Applicant(s)
09/533,798	
Examiner	**Group Art Unit** 1648
	Page 1 of 1

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
	A	5,869,053	2/99	STERN et al.	424	184.1
	B					
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
	N						
	O						
	P						
	Q						
	R						
	S						
	T						

NON-PATENT DOCUMENTS

*		DOCUMENT (Including Author, Title, Source, and Pertinent Pages)	DATE
	U		
	V		
	W		
	X		

* A copy of this reference is not being funished with this Office action.
(See Manual of Patent Examining Procedure, Section 707.05(a).)